FindTrial
Sign In

HPV Infections, Cancer of the Vulva and Therapeutical Success

Influence of Hpv Infections on Therapeutical Outcome of Patients Suffering From Vulvar Cancer and Ist Preinvasive Lesions

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03082950
Enrollment
110
Registered
2017-03-17
Start date
2015-10-31
Completion date
2018-05-31
Last updated
2018-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV, Human Papilloma Virus

Keywords

hpv prevalence, recurrence rate, survival

Brief summary

HPV infections may be responsible for different types of cancer in females. Primary Goal of the study was to identify the prevalence of an hpv affiliation in retrospective-prospective analysed cohort of patients who suffer from vulvar cancer and their preinvasive lesions.

Detailed description

HPV infections may be responsible for different types of cancer in females. Primary Goal of the study was to identify the prevalence of an hpv affiliation in retrospective-prospective analysed cohort of patients who suffer from vulvar cancer and their preinvasive lesions. After having retrospectively identified patients with vulvar cancer incl. their preinvasive lesions in the clinical registry the hpv status of the samples is prospectively analyzed using a new multiplex pcr Array. Two Groups are build: patients with hpv associated vulvar cancer and patients with non-hpv associated vulvar cancer. Then, the rate of patients who respond to radiotherapy within the Groups is analyzed by building Kaplan meier plots according to the patients survival and recurrence rate.

Interventions

DIAGNOSTIC_TESTpolymerase chain reaction

PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.

Sponsors

EUROIMMUN Medizinische Labordiagnostika AG
CollaboratorUNKNOWN
University of Luebeck
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* pts. who suffer from vulvar cancer and their preinvasive lesions * positive informed consent * complete set of data * Treatment in luebeck university

Exclusion criteria

* opposite of above

Design outcomes

Primary

MeasureTime frame
prevalence of hpv infections among pations suffering from vulvar cancer and preinvasive lesions15yrs

Secondary

MeasureTime frame
disease free survival among the groups15yrs

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026